Lv11
90 积分 2024-08-15 加入
Graves disease: latest understanding of pathogenesis and treatment options
19天前
已完结
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
1个月前
已完结
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
1个月前
已关闭
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
1个月前
已关闭
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
1个月前
已完结
Rationalization design, soluble expression and PEG modification of highly active recombinant human-porcine uricase mutant protein
8个月前
已完结
皖公网安备34019202002308
